Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_1209 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_1209 |
| Peptide Name | Penetratin |
| PEPTIDE SEQUENCE (1-letter) | RQIKIWFQNRRMKWKK |
| PEPTIDE SEQUENCE (3-letter) | NA |
| N-terminal modification | NA |
| C-terminal modification | NA |
| Chemical modification | NA |
| Peptide Length | 16 |
| Conformation | Linear |
| Peptide Nature | NA |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | NA |
| Cell Line | NA |
| In vitro CONCENTRATION | NA |
| In vitro METHOD | NA |
| In vitro RESULT | NA |
| ANIMAL MODEL | Male Sprague-Dawley rats |
| In vivo CONCENTRATION | 2.0 mM |
| In vivo MODE OF DELIVERY | Intranasal |
| In vivo METHOD | ELISA |
| In vivo RESULT | L-penetratin increased the systemic absorption of leptin after intranasal administration. |
| ACTION | The intranasal coadministration with L-penetratin could deliver leptin to the brain and in particula |
| TRANSPORT TYPE | Permeability |
| SUBCELLULAR LOCALISATION | Hypothalamus |
| COMBINATION | Combined with leptin |
| PHYSICAL CONDITION | Obesity |
| RESPONSE | NA |
| RESULT | The intranasal coadministration with L-penetratin has a potential to deliver leptin into the therape |
| LABEL | NA |
| PMID | 31926192 |